Skip to main content
European Journal of Human Genetics logoLink to European Journal of Human Genetics
. 2008 Oct 15;17(5):682–686. doi: 10.1038/ejhg.2008.181

GAB2 is not associated with late-onset Alzheimer's disease in Japanese

Akinori Miyashita 1, Hiroyuki Arai 2, Takashi Asada 3, Masaki Imagawa 4, Mikio Shoji 5, Susumu Higuchi 6, Katsuya Urakami 7, Shinichi Toyabe 8, Kohei Akazawa 9, Ichiro Kanazawa 10, Yasuo Ihara 11, Ryozo Kuwano 1,*
PMCID: PMC2986257  PMID: 18854865

Abstract

The ɛ4 allele of the apolipoprotein E gene (APOE) is unequivocally recognized as a genetic risk factor for late-onset Alzheimer's disease (LOAD). Recently, single-nucleotide polymorphisms (SNPs) of the GRB2-associated binding protein 2 gene (GAB2) were shown to be associated with LOAD in Caucasians carrying the APOE-ɛ4 allele through a genome-wide association study. Here, we attempted to replicate the finding by genotyping these SNPs in a large clinical cohort of Japanese. We observed no association of any of the SNPs with LOAD. GAB2 may not be a disease susceptibility gene for LOAD in Japanese.

Keywords: Alzheimer's disease, GAB2, APOE, SNP

Introduction

It is well known that the development of Alzheimer's disease (AD) is consequence of complex interactions between multiple genetic and environmental factors. To date, only the ɛ4 allele of the apolipoprotein E gene (APOE) is universally recognized as a genetic risk factor for late-onset AD (LOAD) in a variety of populations,1, 2, 3 but not in elderly Nigerians.4 As the presence of risk genes other than APOE is speculated,5 many studies have been performed to identify them.

Genome-wide association studies (GWAS) involving high-density single-nucleotide polymorphism (SNP) genotyping technologies have led to great success in the identification of risk genes for various common diseases.6, 7 With regard to LOAD, the GRB2-associated binding protein 2 gene (GAB2) on chromosome 11q was recently identified in Caucasians through GWAS: 10 SNPs of this gene have been shown to be associated with LOAD in APOE-ɛ4 carriers.8 It is noteworthy that the most significant SNP, rs2373115, exhibits an odds ratio (OR) of 4.1 (95% confidence intervals (Cis), 2.8–14.7), which is almost equal to the strong risk effect exerted by the APOE-ɛ4 allele (ɛ3 vs ɛ4, OR=3.2–4.1).2 Furthermore, the following findings with relation to AD neuropathology have been made:8 in LOAD brains GAB2 is detected in highly dystrophic neurons, including neurofibrillary tangle (NFT)-bearing neurons, and interference with GAB2 expression increases TAU phosphorylation, which leads to NFT formation. With this genetic and biological evidence, GAB2 is considered to be a promising candidate for LOAD, although a recent replication study revealed a lack of association of this gene with LOAD in Caucasians.9 Therefore, we here assessed whether or not the genetic association of GAB2 with LOAD can be reproduced in Japanese.

Subjects and methods

Subjects

Blood samples were collected by the Japanese Genetic Study Consortium for AD (JGSCAD): the members are listed in our recent publications.10, 11 The LOAD patients were clinically validated, and satisfied the criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association for a diagnosis of probable AD.12 Non-demented controls living in an unassisted manner in the local community were recruited from among elderly subjects. The Mini-mental State Examination (MMSE) and Clinical Dementia Rating and/or the Function Assessment Staging were used to assess severity of the cognitive impairment. Basic information on the sample sets used is presented in Table 1. The total sample size is 1656 LOAD patients (female, 71.6%) and 1656 controls (female, 58.7%), which is large enough to detect risk alleles assuming OR>1.3 (range of risk allele frequency=0.1–0.9, α=0.05, power=80%). This subject group is referred to as overall sample set All in this study (Table 1). A large proportion (79.4%) of the subjects are the same as in our previous overall sample set.10, 11 To construct two sub-sample sets, the All set was stratified as to the APOE-ɛ4 carrier status: Negative-ɛ4 (LOAD, 790; control, 1378) and Positive-ɛ4 (LOAD, 866; control, 278) (Table 1).

Table 1. Information on sample sets.

        APOE
    AAO/AAE MMSE Genotype Allele
Sample set No. of subjects Mean (SD) Range Mean (SD) Range 2*2 2*3 2*4 3*3 3*4 4*4 ɛ2 ɛ3 ɛ4
Overall set
All                            
  LOAD 1656 73.1 (6.2) 60–85 16.5 (6.7) 0–30 1 53 21 736 686 159 76 2211 1025
  Control 1656 75.3 (6.1) 64–96 28.3 (1.7) 24–30 4 126 17 1248 248 13 151 2870 291
Subsets                            
Negative-ɛ4                            
  LOAD 790 73.7 (6.4) 60–85 16.2 (7.2) 0–30 1 53 0 736 0 0 55 1525 0
  Control 1378 75.4 (6.2) 64–96 28.3 (1.7) 24–30 4 126 0 1248 0 0 134 2622 0
Positive-ɛ4                            
  LOAD 866 72.5 (5.9) 60–85 16.9 (6.3) 0–30 0 0 21 0 686 159 21 686 1025
  Control 278 75.1 (5.8) 64–95 28.3 (1.7) 24–30 0 0 17 0 248 13 17 248 291

AAO, age at onset; AAE, age at examination.

This study was approved by the Institutional Review Board of Niigata University, and by all participating institutes. Informed consent was obtained from all controls and appropriate proxies for patients, and all subjects were anonymously subjected to SNP genotyping.

Genotyping

Genomic DNA preparation and genotyping were described previously.10. We did not genotype additional SNPs to the 10 ones reported by Reiman et al,8 as strong LD (∣D′∣>0.8) was observed across the GAB2 (see Supplementary Figure 1).

Statistical analysis

We carried out a Hardy–Weinberg equilibrium (HWE) test based on an exact test, single SNP and haplotype-based case–control studies, haplotype inference, and computation of LD measures (D′). As an estimate of the relative risk of disease, OR with 95% CIs of each marker or haplotype was calculated from a 2 × 2 contingency table. For all statistical analyses mentioned above, we used SNPAlyze® software version 6.0.1 (DYNACOM): the analytical methods were described in detail elsewhere.11 For evaluation of the LD block structure in and around GAB2, Haploview software version 3.32 was used. We considered P<0.05 statistically significant.

Results

To determine whether the GAB2 association can be replicated in Japanese or not, we analyzed the 10 SNPs using a total of 3312 clinical subjects for genotyping (see Supplementary Figure 2). These SNPs are encompassed by GAB2 (Table 2), which consists of 10 exons and spans about 202.4 kb on chromosome 11. To examine population differences in the allele frequencies of the SNPs, we first assessed the HapMap genotype data (http://www.hapmap.org/index.html) for four populations: Japanese in Tokyo (JPT), US Utah residents with northern and western European ancestry (CEU), Han Chinese in Beijing (CHB) and Yoruba in Ibadan, Nigeria. These 10 SNPs for JPT exhibited similar allelic frequencies to CHB, but not to CEU: for example, the frequencies for allele G of SNP rs2373115 were 0.47 for JPT and 0.89 for CEU (see Supplementary Figure 3). HWE exact tests were performed to detect genotyping errors. SNP rs7101429 slightly deviated from the HWE in the All (P=0.0497) and Negative-ɛ4 (P=0.0416) sample sets in LOAD. Remaining nine SNPs were in HWE (P≥0.05) (Table 2).

Table 2. SNP information on 10 GAB2 SNPs.

        All Negative-ɛ4 Positive-ɛ4
      Allele   Allele frequency HWE   Allele frequency HWE   Allele frequency HWE
dbSNP Physical position (bp) SNP position Maj Min GSR (%) Maj Min LOAD Control GSR (%) Maj Min LOAD Control GSR (%) Maj Min LOAD Control
rs901104 77 608 147 intron 9 G A 99.1 0.58 0.42 0.1417 0.5789 99.3 0.57 0.43 0.1894 0.8252 98.6 0.58 0.42 0.4388 0.3866
rs1385600 77 613 814 exon 5 A G 99.7 0.56 0.44 0.0792 0.6180 99.7 0.56 0.44 0.0962 0.7433 99.7 0.57 0.43 0.4042 0.6249
rs1007837 77 618 724 intron 3 T C 98.4 0.56 0.44 0.0964 0.4818 98.3 0.56 0.44 0.1102 0.6206 98.7 0.57 0.43 0.4421 0.5383
rs2510038 77 643 682 intron 2 G A 99.0 0.57 0.43 0.0695 0.3665 99.0 0.56 0.44 0.0944 0.5456 99.0 0.58 0.42 0.3633 0.3910
rs4945261 77 667 908 intron 2 G A 98.5 0.57 0.43 0.0768 0.4817 98.6 0.56 0.44 0.0582 0.6203 98.2 0.58 0.42 0.5278 0.6205
rs7101429 77 670 615 intron 1 A G 99.0 0.56 0.44 0.0497 0.5479 99.0 0.56 0.44 0.0416 0.7019 98.9 0.57 0.43 0.4857 0.5344
rs10793294 77 674 051 intron 1 C A 98.0 0.80 0.20 0.3389 0.2567 98.3 0.80 0.20 0.7184 0.0780 97.5 0.79 0.21 0.0905 0.2930
rs4291702 77 678 896 intron 1 G A 98.4 0.57 0.43 0.0681 0.5456 98.4 0.56 0.44 0.0794 0.6593 98.3 0.58 0.42 0.3992 0.7089
rs7115850 77 722 719 intron 1 G C 99.7 0.57 0.43 0.1194 0.4842 99.8 0.56 0.44 0.0960 0.7017 99.4 0.58 0.42 0.5772 0.4600
rs2373115 77 768 798 intron 1 C A 98.8 0.56 0.44 0.0770 0.5824 99.0 0.56 0.44 0.0930 0.7846 98.3 0.57 0.43 0.4019 0.4606

The genomic position of each SNP is according to NCBI build 36.2. The allele frequency for each sample set was calculated by combining LOAD and control subjects. Maj, major; Min, minor; GSR, genotyping success rate; HWE, P-value of Hardy–Weinberg equilibrium exact test (bold value indicates statistical significance at P<0.05).

A single SNP case–control study (χ2 test) was then carried out. We did not observe any significant association of the SNPs with LOAD in not only the All set but also the two subsets (Negative-ɛ4 and Positive-ɛ4) (Table 3). Multiple logistic regression analysis, with adjustment for the carrier status of the APOE-ɛ4 allele, age and gender as covariates, did not reveal any significant evidence of association (data not shown).

Table 3. Genotypic and allelic associations.

    Genotype Allele
    LOAD Control     LOAD Control    
Sample set dbSNP Maj Ht Min Maj Ht Min P-value (d.f.=2) Maj Min Maj Min P-value (d.f.=1) OR (95% CIs)
Overall set
All rs901104 559 768 306 554 793 301 0.8206 1886 1380 1901 1395 0.9539 1.00 (0.91–1.11)
  rs1385600 550 775 326 518 804 328 0.473 1875 1427 1840 1460 0.4007 1.04 (0.95–1.15)
  rs1007837 541 769 324 514 788 324 0.6366 1851 1417 1816 1436 0.5163 1.03 (0.94–1.14)
  rs2510038 550 766 321 531 789 321 0.7156 1866 1408 1851 1431 0.6263 1.02 (0.93–1.13)
  rs4945261 549 763 318 523 789 319 0.5864 1861 1399 1835 1427 0.4978 1.03 (0.94–1.14)
  rs7101429 541 764 329 524 797 323 0.6084 1846 1422 1845 1443 0.7602 1.02 (0.92–1.12)
  rs10793294 1044 518 54 1035 519 77 0.1347 2606 626 2589 673 0.2034 1.08 (0.96–1.22)
  rs4291702 555 760 314 525 789 315 0.5021 1870 1388 1839 1419 0.438 1.04 (0.94–1.15)
  rs7115850 551 777 321 530 799 323 0.6982 1879 1419 1859 1445 0.5612 1.03 (0.93–1.13)
  rs2373115 543 763 321 519 800 326 0.5071 1849 1405 1838 1452 0.4355 1.04 (0.94–1.15)
Subsets                            
Negative-ɛ4 rs901104 265 365 152 456 666 249 0.6473 895 669 1578 1164 0.8361 1.01 (0.89–1.15)
  rs1385600 262 365 162 425 672 275 0.4462 889 689 1522 1222 0.579 0.97 (0.85–1.09)
  rs1007837 255 362 162 421 659 272 0.5943 872 686 1501 1203 0.7715 0.98 (0.87–1.11)
  rs2510038 260 361 160 436 661 268 0.617 881 681 1533 1197 0.8747 0.99 (0.87–1.12)
  rs4945261 264 357 159 429 660 269 0.4285 885 675 1518 1198 0.5942 0.97 (0.85–1.10)
  rs7101429 258 355 165 427 669 273 0.3526 871 685 1523 1215 0.8232 0.99 (0.87–1.12)
  rs10793294 519 228 27 873 418 67 0.2019 1266 282 2164 552 0.0953 0.87 (0.74–1.02)
  rs4291702 264 357 156 432 660 265 0.4674 885 669 1524 1190 0.6136 0.97 (0.85–1.10)
  rs7115850 263 365 162 433 670 271 0.5133 891 689 1536 1212 0.751 0.98 (0.87–1.11)
  rs2373115 259 358 159 425 672 274 0.4068 876 676 1522 1220 0.5528 0.96 (0.85–1.09)
Positive-ɛ4 rs901104 294 403 154 98 127 52 0.9071 991 711 323 231 0.9743 1.00 (0.82–1.21)
  rs1385600 288 410 164 93 132 53 0.9997 986 738 318 238 0.9994 1.00 (0.82–1.21)
  rs1007837 286 407 162 93 129 52 0.9866 979 731 315 233 0.9244 0.99 (0.82–1.20)
  rs2510038 290 405 161 95 128 53 0.9637 985 727 318 234 0.9757 1.00 (0.82–1.21)
  rs4945261 285 406 159 94 129 50 0.9616 976 724 317 229 0.7902 0.97 (0.80–1.18)
  rs7101429 283 409 164 97 128 50 0.7886 975 737 322 228 0.5107 0.94 (0.77–1.14)
  rs10793294 525 290 27 162 101 10 0.6649 1340 344 425 121 0.3862 1.11 (0.88–1.40)
  rs4291702 291 403 158 93 129 50 0.9981 985 719 315 229 0.9674 1.00 (0.82–1.21)
  rs7115850 288 412 159 97 129 52 0.8926 988 730 323 233 0.8083 0.98 (0.80–1.19)
  rs2373115 284 405 162 94 128 52 0.9571 973 729 316 232 0.8382 0.98 (0.81–1.19)

Maj, major; Ht, heterozygous; Min, minor; d.f., degree of freedom.

Pairwise LD measures, D′, of the SNPs are given in Supplementary Table 1. We found a strong correlation (∣D′∣>0.93) between the 10 SNPs in each of the three sample sets. No difference in the LD block structure was observed between LOAD and control subjects. Using the HapMap genotype data for JPT and CEU, we further performed in silico LD mapping of a genomic region spanning about 500 kb. It was found that GAB2 was completely encompassed by a highly structured single LD block in both JPT and CEU (see Supplementary Figure 1). However, there was an evident difference in the LD block boundary in the 5′ region of GAB2: in JPT, we observed a definitive break point in the block, but not in CEU (see Supplementary Figure 1).

In the LD block, including the whole GAB2, three common haplotypes (frequency >1%), H1, H2 and H3, were inferred in all sample sets (see Supplementary Table 2). Haplotype H2 consisted of all major alleles of the 10 SNPs. In every sample set, no haplotypes exhibited significant differences between LOAD and controls (see Supplementary Table 2).

Discussion

Recently, it was shown that GAB2, encoding a scaffolding adaptor protein involved in several signal-transduction pathways, is associated with LOAD in Caucasians.8 At SNP rs2373115 located within this gene, a noticeable significance in allelic association (Pallele=9.7 × 10−11) has been observed.8 Interestingly, the disease risk of this gene is increased by the APOE-ɛ4 allele: maximum OR of 24.6 (95% CIs, 7.4–116.8) was computed in carriers with both the APOE-ɛ4 and GAB2 SNP rs2373115 risk (G) alleles,8 suggesting a genetic interaction between these two genes. On the basis of these findings, we attempted here to replicate the genetic association of GAB2 with LOAD in Japanese. In Reiman et al's study,8 neuropathologically well-characterized brains of Caucasians were largely used (LOAD, 643; control, 404), whereas we utilized only clinically confirmed subjects (LOAD, 1656; control, 1656). However, no evidence of association of this gene was obtained in the All, Negative-ɛ4 and Positive-ɛ4 sets (Table 3). GAB2 may not be a disease susceptibility gene for LOAD in Japanese.

As a possible explanation for the discrepancy between our results and the initial study,8 we consider an ethnic difference (Japanese vs Caucasian), genotyping technology (TaqMan® vs GeneChip® genotyping) and subject selection (clinically vs neuropathologically verified subjects) described above. With regard to the ethnic difference, Wright's FST statistic has been proposed for clarifying the level of between-population differentiation.13 FST is 0.145 (estimated from 3845 SNPs) among Asian (Japanese and Chinese), African-American and European-American, and 0.013 (estimated from 8801 SNPs) between Japanese and Chinese.14 Across the 10 GAB2 SNPs, we calculated FST using HapMap genotype data of JPT, CHB and CEU. The mean FST of these SNPs was 0.012 (standard deviation (SD), 0.006; range, 0.000–0.025) between JPT and CHB, and 0.219 (SD, 0.077; range, 0.164–0.435) between JPT and CEU. These data indicate that a higher level of genetic differentiation exists between JPT and CEU for GAB2. Recently, Chapuis et al9 could not replicate the initial finding8 even in European-Caucasian subjects (N>3000), suggesting that GAB2 is at best a minor disease susceptibility gene for LOAD. A meta-analysis is needed to confirm the association of GAB2 with LOAD.

Acknowledgments

We thank the patients with AD and their families, and the control individuals for their participation in this study. We are very grateful to the members of JGSCAD for the collection of blood samples: the members were listed previously.10, 11 We also thank K Horigome, M Hirose, N Yahata, K Takadono, N Takei, T Tsukie, T Gohno and M Asakura for their expert technical support, and NJ Halewood for critical reading of the manuscript. This study was supported by KAKENHI (Grant-in-Aid for Scientific Research) on Priority Areas – Comprehensive Genomics – (RK). There is no conflict of interest to declare.

Footnotes

Supplementary Information accompanies the paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)

Supplementary Material

Supplementary Material

References

  1. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. JAMA. 1997;278:1349–1356. [PubMed] [Google Scholar]
  2. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39:17–23. doi: 10.1038/ng1934. [DOI] [PubMed] [Google Scholar]
  3. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923. doi: 10.1126/science.8346443. [DOI] [PubMed] [Google Scholar]
  4. Gureje O, Ogunniyi A, Baiyewu O, et al. APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians. Ann Neurol. 2006;59:182–185. doi: 10.1002/ana.20694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Daw EW, Payami H, Nemens EJ, et al. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet. 2000;66:196–204. doi: 10.1086/302710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Sladek R, Rocheleau G, Rung J, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007;445:881–885. doi: 10.1038/nature05616. [DOI] [PubMed] [Google Scholar]
  7. Wellcome Trust Case Control Consortium Genome-wide association study of 14 000 cases of seven common diseases and 3000 shared controls. Nature. 2007;447:661–678. doi: 10.1038/nature05911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Reiman EM, Webster JA, Myers AJ, et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron. 2007;54:713–720. doi: 10.1016/j.neuron.2007.05.022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chapuis J, Hannequin D, Pasquier F, et al. Association study of the GAB2 gene with the risk of developing Alzheimer's disease. Neurobiol Dis. 2008;30:103–106. doi: 10.1016/j.nbd.2007.12.006. [DOI] [PubMed] [Google Scholar]
  10. Kuwano R, Miyashita A, Arai H, et al. Dynamin-binding protein gene on chromosome 10q is associated with late-onset Alzheimer's disease. Hum Mol Genet. 2006;15:2170–2182. doi: 10.1093/hmg/ddl142. [DOI] [PubMed] [Google Scholar]
  11. Miyashita A, Arai H, Asada T, et al. Genetic association of CTNNA3 with late-onset Alzheimer's disease in females. Hum Mol Genet. 2007;16:2854–2869. doi: 10.1093/hmg/ddm244. [DOI] [PubMed] [Google Scholar]
  12. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939–944. doi: 10.1212/wnl.34.7.939. [DOI] [PubMed] [Google Scholar]
  13. Wright S. Evolution and the Genetics of Populations; the Theory of Gene Frequencies. Vol. 2. University of Chicago Press: Chicago; 1969. pp. 294–295. [Google Scholar]
  14. Marchini J, Cardon LR, Phillips MS, Donnelly P. The effects of human population structure on large genetic association studies. Nat Genet. 2004;36:512–517. doi: 10.1038/ng1337. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Material

Articles from European Journal of Human Genetics are provided here courtesy of Nature Publishing Group

RESOURCES